Immunotech Laboratories Inc (IMMB)

[Jeff Taitano]

I'm not sure they can apply without audited financials submitted, isn't that a prerequisite?

In another ticker I'm in, the company applied over a month ago and it is still being processed.

[Dodgeball]

$IMMB either a) still owns the IP rights, or b) owns a big piece of $ENZC. It's one or the other. Understand that getting current costs money. But Harry can (and should) still file an 8K to clear that up.

[Jeff Taitano]

I bought a bottle in January and it made me feel more energetic. Not sure if it was the hemp, overthinking, or the pepsin actually boosting my immune system.

Also I have an email from their team confirming it was from the Enzolytics NDI # 1083.

They have another website too and it's all under the pubco - PBIO.


.........

On another note, in the new filings dropped today for Enzolytics there are slight changes to the verbiage and actual numbers pertaining to the asset purchase agreement on March 26, 2018.

[NanoEE]

No, I did not see this.

Is this the BSSP side of the business or a totally different company.

I don't see a full contact description, just the email blasted everywhere.

I am curious though, I just may have to buy a bottle.

[NanoEE]

I am under speculation that there is a lot of paperwork to sort through(A LOT), and I say that because Enzolytics Inc. has not filed for QB yet and its going to take some time to sort through it all.

I noticed on a couple companies in the OTC trying to file for QB have been denied. I bet that ENZC is denied as well in their 1st attempt and 2nd attempt.

[Dodgeball]

Harry needs to get $IMMB filings up to date before someone makes a custodianship play.

[Jeff Taitano]

Y'all know about this product too right?

https://immunazin.com/

[NanoEE]

HA!!!

"We gratefully acknowledge Harry Zhabilov's years of commitment to the Company that are making possible the partnerships and agreements now being finalized. As a result of his efforts, we have another European transaction which we expect to consummate and report in the coming week."

Hmmmm, IMMB?!?!

I love this comment by Harry.

"For many years, we have been developing and strengthening the relationships that are now leading to our current significant partnerships. With the advances the Company is making toward preparation for and completion of clinical trials in Europe, which will lead to approval from the EMA, we are meeting our goal of bring our technology to those in need", said Harry Zhabilov, CSO.


https://finance.yahoo.com/news/enzolytics-inc-announces-grant-distributorship-133000568.html

[NanoEE]

I could see that, but that is back to my whole point Harry is wanting to make lots of money and how he goes about it doesn't phase him.


I want to point out another person of interest:

Dr. Dimiter Dimitrov

https://www.otcmarkets.com/stock/CUBT/news/Curative-Biotechnology-Inc-Announces-FINRA-Ticker-Symbol-Change-From-CTYX-To-CUBT?id=300576

Well known and is on the same medical adventure. Just curious as to who gets there faster. I tried to see if there was also a connection to IMMB or even ECPO and no such luck(I didn't spend too much time trying to dig deep either).

[rbtree]

So I see, Elk. I became aware of ENZC's big move last fall, as it came along in lockstep with the across the board (almost) huge gains in stinky pinks. I just now followed Porgie's post stream over to IMMB, and see the same scammer behind both.

No wonder ENZC is now off its highs by over 80%. Of course the pumpers are screaming manipulation when it's obviously dilution--via toxic debt conversion.

[Dodgeball]

Harry Z Jr seems very content to hide the $IMMB assets from public view. Maybe because of his position with $ENZC. Perhaps his ownership in $IMMB is very underestimated in the scheme of things.

[NanoEE]

Harry SR had something that proved effective with Viral Genetics INC..

But never filed a patent in the US or tried and was never stamped?!?!

http://www.translatetheweb.com/?ref=SERP&br=ro&mkt=en-US&dl=en&lp=ZH-CHT_EN&a=http%3a%2f%2fwww.nafinance.com%2fListed_Co%2fChinese%2fviral.htm

Through the companies we know of, "this" HIV vaccine has taken four(five possibly) acronyms so far(I am assuming possibly more). If I had more time to go over all patents filed for this "vaccine", my assumption they are all one in the same Harry Z. is trying to find the right verbiage that passes this in the US Patent office.

VGV-1(Viral Genetics)
HIV-1(ECPO Patent)
IPF-1(ECPO/IMMB Patent)
ITV-1(The Zhabilov Patent)

[NanoEE]

Just food for thought.

I have to dig into some of this later.

https://www.legacy.com/obituaries/latimes/obituary.aspx?pid=332435

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163170396

I don't know why, but I was curious on how(and still am) Fauci knew there was something brewing with The Zhabilov's. Where is the connection.

But with MCET and Viral Genetics the rabbit hole may go deeper.

Harry Zhabilov JR is only a Chemist and does not carry a PhD, kinda makes sense that Harry is reaching out to certain people and companies because he doesn't understand, "What it takes to get there." Which may make sense to some bad ties with IMMB BG, Harry saw a dead end there as well and went off in a different direction.

[Dodgeball]

Looks like IMMB BG rights flow through $IMMB. And although Dimitar did get shares in $ENZC as an independent award, what I don't see is any 13D/13G filings where $IMMB received any $ENZC shares to transfer the IP and IMMB BG stake over to $ENZC. If $ENZC purchased the IP and IMMB BG ownership, then $IMMB owns quite a bit of $ENZC. If that transaction was never final, then $IMMB owns the assets. As the current president of $IMMB, Harry really needs to update the filings, if not in full, then at least an 8K detailing the stock for asset transaction. Also, curious why Harry is trying to break with IMMB BG when there is an ownership stake, either through $ENZC or $IMMB.

[NanoEE]

Harry President of IMMB, owns 49% of IMMB BG

Dimitar President of IMMB BG owns 51%, owns ~70million shares of ENZC

As I read this more(https://www.immunotechlaboratoriesbg.com/news), Does Dimitar own 51% of IMMB BG or IMMB?!?! I am assuming IMMB BG because of his LinkedIn page.

And if I am not mistaken I thought the licensing agreement was signed with IMMB not IMMB BG to manufacture ITV-1?!?! The web site says IMMB BG, but the SEC doc says IMMB.

https://www.sec.gov/Archives/edgar/data/1137117/000109690609000212/immb8k121208ex10-1.htm

Even Dimitar verbiage is very vague in who has what and what is each other doing for what company.

Is it because of the language barriers we are seeing errors?

Curious about this connection in Dimitars LinkedIn,

https://www.linkedin.com/in/ronald-moss-18130212/

Touted work(pretty impressive), then why is it so hard to get approval with this guy on your side?!?!

[NanoEE]

You want it, here it is, granted this is a study in 1999, but important none-the-less.

https://pubmed.ncbi.nlm.nih.gov/10658363/

When you have claimed something with out solid results(data), and are shut down by two two other labs over your claims, the Lab world won't jump to your aid until they see solid results. Toxicology report is probably on the bottom of the stack of more "important" reports. That is Harry's fault.

So, Enzolytics Inc.(and I use the company name not the stock ticker), has work to do to prove it self-worth towards investors.

For the combined materials from Bioclonetics and Enzolytics(prior merger), I am interested in the Clone3 material(medicine) compound structure(aka drug compound structure). Mostly in the chain structure.

[Dodgeball]

The who owns what mystery deepens again. If $ENZC owns 49% of IMMB BG, then it paid $IMMB for such rights, along with the ITV-1 rights, with a big block of $ENCZ stock. Conversely, if the stock was never paid to $IMMB, then it owns 49% of IMMB BG and the ITV-1 rights. Harry, of course, is still president of $IMMB, so he indirectly controls the rights and IMMB BG either way, which leads to the question of why he is trying to put space between $ENCZ and IMMB BG.

[elkonig]

IMMB was suspended by the SEC 7 years ago for putting out fraudulent information that the ITV-1 drug that Zhavbilov had developed was a cure for the Ebola virus. He played the gane selling the same snake oil product at BSSP and VGLS. Now hes doing the same thing at ENZC.

[NanoEE]

This has to be IMMB.

https://rosettalifecarebg.com/

At Mode 1, on the Rosetta web site, they have the same verbiage as in IMMB's website.

https://www.immunotechlaboratoriesbg.com/f-i-immunomodulator

When you get to the ITV Survey, and they start talking about the GP41 and GP120.

https://backend.otcmarkets.com/otcapi/company/financial-report/275843/content

On January 15, 2018, the merger agreement with Immunotech Laboratories, Inc. was terminated except for Section 1.03(d)(i) which relates to the appointment of Harry Zhabilov as Chairman and CEO of ECPO which remained in effect.

Page F-33
March 22, 2021, The Company has entered negotiations with Pro Wave Ad Product ("PWA"), a Bulgarian Company, to supply the raw material for PWA's Contract in India for the production of a spray modulating the immune system under U.S. Patent No. 8,309,072 owned by Zhabilov Trust.

March 22, 2021, As a result of the necessity to perform Clinical trials under the EMA guidelines, the agreements with IMMB BG, which were in default, have been cancelled and superseded by the new agreements with IMBL and PAW. The ITV-1 treatment that successfully completed Phase 3 clinical trials on August 7, 2014, with the Final Report being issued in November of 2016 by Assoc. Prof. Ivaylo Elenkov, MD, Chief researcher at the Specialized Hospital for Active Treatment of Infectious and Parasite Diseases. This report and the associated clinical trials were conducted under Bulgarian Drug Administration(BDA) guidelines. With Bulgaria joining the EMA in April of 2019, the BDA can no longer issue permits for mass use for the HIV/AIDS virus. Under the Company's new business arrangement with International Medical Partners, Ltd. (IMBL), new clinical trials are being planned and scheduled with Clinical Design, a Clinical Research Organization (CRO) in Bulgaria. The Company is finalizing negotiations with a Contract Manufacturer, also located in Bulgaria, for the production of the ITV-1 Immunotherapy treatment. The new clinical trials for the Patented and licensed ITV-1 treatment under the EMA guidelines will be submitted upon completion. When the EMA permit for mass use is issued, the Company plans to pursue Federal Drug Administration (FDA) approval under the Mutual Recognition Agreement between the FDA and EMA.

Spray Modulating, which the website touts.

HERE IT IS:
PRO Wave, Valentine is connectedBAM!!!

https://papagal.bg/person/48085159552C9A812EF81EA2C8D0334845377DAD54BE66B16CEB7302F4BDA0A3

[Dodgeball]

Interesting.

BSSP tie?!?!

[NanoEE]

Knew I read that somewhere.

BSSP tie?!?!

[Dodgeball]

From $IMMB annual report 12/31/16.

Item 8). Officers, Directors, and Control Persons

A. Names of Officers, Directors, and Control Persons

1.) Harry H. Zhabilov – President and Chairman of the Board and owner of 40,000,000 shares of Series A Preferred (66%), Series B Preferred 90,000,000 shares of Series B Preferred (4%) and 16,678,000 Common shares (less than 3%),

2.) Valentine Iordanov Dimitrov – Director

3.) Dimitri Savov - owner of 120,000,000 Series B (60%) and 73,000,000 Common shares (12.7%).

https://backend.otcmarkets.com/otcapi/company/financial-report/165977/content

[NanoEE]

Someone found this on the “other” ticker.

Somewhat important,
https://rosettalifecarebg.com/

Especially at the referenced book section on the bottom left corner(shows shows virus adaptation).

This one is more important,
https://enzoimmune.com/

Here they list FDA Approval and the patent to The Zhabilov Trust.

Valentine Dimitrov sounds very familiar when I have more time I will dig into his name.
Somehow tied to Harry.

[L0GiK]

I’m new to everything, what does it mean with something trades on “expert”?

[Dodgeball]

Still trades, but on Expert since Harry hasn't kept up with the filings. Have to wonder why. Maybe $IMMB is the company that should have the billion dollar market cap that $ENZC had before the dust up.

[Dodgeball]

Pretty clear that $IMMB still has "the goods" one way or another. Either $ENZC gave them almost 20% ownership (or more, but to your point, filings are very vague) of the "new" company for the assets, or $IMMB still owns all the assets and IP rights. The lack of clarity might have to do with the "apparent" public pi*sing contest between Harry and Dimitar, which really makes no sense at all from a business perspective. Maybe Harry hedging both sides? He's been known to be pretty shrewd.

[NanoEE]

You are right, it is still a very vague financial reporting(although it is in an unofficial reporting).

And why “that” board gets so offensive over information or seeking information is beyond me.

I love that in the report Enzolytics cites a company that will still produce the ITV-1 overseas but they keep that company under raps in divulging the company name. I bet it’s IMMB producing without a licensing agreement.

The Zhabilov Trust signs an agreement with IMMB, then IMMB starts building/remodeling a building to manufacture the ITV-1. If there already is a facility to start production why not use it, right?!?!

[L0GiK]

Did they suspend trading on this ticker?

[Dodgeball]

That makes sense. There are a lot of reasons to start with a clean shell, which leave the original company sitting on an equity position in the process. One thing to consider: if $IMMB is holding on a big position of $ENZC shares, they are basically off the table to the market, which makes the $ENZC tradable float smaller, which in the end is a good thing for both entities. It also gives Harry considerably more voting power, since he controls $IMMB. That is where clarity on the issue is useful. For perspective, look at the trade history for $IMMB the week of 2/8. Somebody got "interested" after a long quiet period. Not sure I'd call $IMMB "abandoned," since if the transfer happened, it got equity and a note in return and which are now "quietly" sitting on the books.

[Jeff Taitano]

You're right - we do need to see the receipts. I'm speculating with the following, but I think that Harry had a stack of papers and handed them to Charles who handed them to the M&B to finish.

I'm also speculating that IMMB is just going to be left as is right now. Would it need to be filed with both companies? Or could it be filed with ENZC only?

Right now it appears to me that IMMB is being abandoned after all of the assets were transferred into ENZC.

From what I see, Harry just wanted a clean company to do business with while he completed his science. And Charles wanted to take his company public. They both probably met through Gaurav and they all likely thought that the two companies would be able to combine their tech. Now it's a mini biotech slated to license its tech to the big players.

[Dodgeball]

It does appear that way. But then there is nothing to confirm the March 26 asset purchase by $ENZC, and no filing by $IMMB to indicate receipt of anything. One would think that the shares of $ENCZ common stock would require registration. But no filing to that effect. And the note? How much? Not detailed anywhere in the $ENZC filing. It would be easy to clean up the filings, but for some reason Harry is not doing it.

[Jeff Taitano]

It appears that the agreement from March 9th 2017 was replaced by the agreement from March 26th, 2018. This new agreement would have taken place after Harry was denied retiring the IMMB symbol. The filing even states that there was a deficiency letter issued on October 25th, 2017 and the agreement was terminated on January 15, 2018.

So it makes sense that the common shares are still being traded. They were never transferred because that agreement was superseded by the agreement on March 26th, 2018.

[Dodgeball]

I believe the shares you are talking about were restricted shares paid to individuals for services.

But what of the common stock?

Recall that this was to be an exchange. And if the exchange occurred, then how would there be shares of $IMMB left to trade? And shares of $IMMB are most certainly still trading. Per the $ENZC filing:

On March 9, 2017, the Company entered into an agreement with the shareholders of Immunotech Laboratories, Inc. (Immunotech) to acquire all of the outstanding shares, both preferred and common stock. The 60,000,000 million Immunotech Series A preferred shares are being exchanged one for one for the Newly Created ECPO Preferred Series A with the exact same voting preference as the Immunotech Series A preferred. Immunotech’s 200 Million outstanding Series B Preferred are being exchanged two for one but do have a voting preferenceand shall be exchanged for 100 Million Series B Preferred shares of ECPO with the exact same voting preferences as the Immunotech Series B Preferred. The Company will issue 291,578,947series B preferred in exchange of 574,964,967 of common stock of Immunotech. This transaction is still in process. Currently the Company has acquired voting control and majority ownership of Immunotech Laboratories, Inc. At the effective time of the Acquisition, all options to acquire common stock of Immunotech issued and outstanding, whether vested or unvested, shall automatically be converted into and become options to purchase shares of Common Stock. Upon conversion of the Newly Created ECPO series B the shareholders of IMMB participating in the Share Exchange Agreement will own 80% of the issued and outstanding of ECPO. No common stock of ECPO will be issued until the Newly Created Preferred Series B is Converted.

Moreover, according to the transfer agent, 574,964,967 shares of IMMB are STILL outstanding. How could this be if there was an exchange?

IMMB Shares Outstanding

[Jeff Taitano]

The consideration for the agreement was the secured notes, the shares and the debts paid.

If you look at the latest yearly for IMMB and compare the names to the most recent filing for ENZC you can see that the shares were transferred over.

Also, if you look at the filings for ENZC you will notice that they issued a TON of shares after the IMMB transition showing all of the shares transferred over.


One thing I will be on the same page with y'all about is seeing the updated license agreements. That would be nice to have.


Oh, and have you seen the new ENZC PR? I know it's not an SEC filing, but I doubt Charles would be risking losing his license and committing securities fraud by making false claims.

As a result of the necessity to perform Clinical trials under the EMA guidelines, the agreements with IMMB BG, which were in default, have been cancelled and superseded by the new agreements with IMBL and PAW.

[Dodgeball]

That's an interesting perspective on contract law, generally in which an agreement must be matched with consideration, otherwise it's only as good as good as a handshake. Where is the consideration? What did $IMMB receive for the transfer? Under the "agreement," $IMMB was to own 80% of $ENZC. Did that transaction ever happen? That, my friend, is the question that needs to be answered.

Because Harry was the majority owner and in control of IMMB - he had the authority to enter into an agreement with ENZC.

Which is how he transferred all of the assets into ENZC.

When you enter into an agreement its final. There is no "receipt" necessary.

[NanoEE]

You play the investments as you see, I play it as I see it.

BSSP, ENZC, and IMMB I am invested in all of them. If one hits of the three, who cares about the other two.

Playing the numbers, whatever the company.

Yeah, Charles runs the game, we knew that was going to be the direction from the merger.

Harry wears a terrible business suit.

[Jeff Taitano]

ITV is only half the cake - Charles controls the whole game.

I've researched BSSP, IMMB, IMMB BG, ENZC et al ad infinitum.

Keep buying IMMB if you're a believer.

I'll keep holding my ENZC shares.

Let's reconvene when the dust settles in Sofia.

[NanoEE]

Hey welcome big cat JT.

Are you fighting with The Resistance or did you hole up on the Death Star in your fight?

So big kicker here, Harry is not a business man, so not a business man, as you may have noticed.

And with that bit of knowledge you may have started connecting the dots, that a lot of things were said and a lot of things were not done by Harry. My guess is he would rather sit in a lab then pushing papers.

This is where Charles comes in, Charles has clean up work on the administrative side, lots of it. But for Charles to do his work, he needs a lot of time. So my question to Charles, why mess around with another “company” and establish it in Europe, hmmmmm. And no, I am not calling to waste my time and Charles time.

When Charles has TIES to cut. Until I see SEC docs clearing things up all of this is still a cluster bomb, waiting to go off.

When all is said and done The Zhabilov Trust can walk away and sell their patent for lots and lots of moola, TO ANYONE COMPANY.

Welcome to the dark side.

Stay thirsty my friend.

[NanoEE]

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162661789

[Jeff Taitano]

Thank you for coming to my ted talk.

[Jeff Taitano]

But feel free to not buy ENZC!!!! I'm trying to get more shares so the less people buying in the better for me - when institutions start buying retail won't matter, so I'm accumulating as much as possible right now.

[Jeff Taitano]

I wouldn't be surprised if Panda was Dimitar or paid by Dimitar.

[Jeff Taitano]

Also, failed to acknowledge anything that didn't fit their narrative - so it was completely biased.

[Jeff Taitano]

Panda got paid to post that article and gets .01 for every view.

[Cass]

Interesting article on ENZC published in Seeking Alpha 15th March:
'ENZC is surrounded by controversy and could be worthless'.

[Jeff Taitano]

Because Harry was the majority owner and in control of IMMB - he had the authority to enter into an agreement with ENZC.

Which is how he transferred all of the assets into ENZC.

When you enter into an agreement its final. There is no "receipt" necessary.

[Jeff Taitano]

This is when Harry gave up trying to save the Immunotech Laboratories, Inc as a company and moved forward with the following in order to transfer the assets.

On January 30, 2018, a new Corporate action was filed by the Company to change its name from Eco-Petroleum Solutions, Inc. to Enzolytics, Inc. to better represent the new business strategy. The Corporate action was approved on March 22nd and the ticker symbol was changed from ECPO to ENZC. The amendment to the Articles of Incorporation in the state of Delaware were filed on January 17, of 2018 changing the name to Enzolytics, Inc.

https://backend.otcmarkets.com/otcapi/company/financial-report/270351/content

[Jeff Taitano]

Harry tried to retire IMMB in order to change Eco-Petroleum Solutions, Inc into Immunotech Laboratories, Inc. but it failed.

On October 25, 2017, the Company’s subsidiary Immunotech Laboratories, Inc. submitted a request to for the retirement of the Immunotech Laboratories, Inc. symbol IMMB from the OTC Market. The request was subsequently denied, and a deficiency letter issued resulting in the termination of the merger agreement.

https://backend.otcmarkets.com/otcapi/company/financial-report/270351/content

[Jeff Taitano]

https://backend.otcmarkets.com/otcapi/company/financial-report/270351/content

The name change attempt for ECPO was not allowed because it still was tied to IMMB

On July 21, 2017, the Company submitted a Corporate Action requesting a name and symbol change, as a required by the merger agreement, to change the name of the Company from Eco-Petroleum Solutions, Inc. to Immunotech Laboratories, Inc. to indicate the Company’s entrance into the Drug Development Industry for Immunotherapies. The Company has received comments and responded and expects the process to be completed shortly. The request was subsequently withdrawn, and the merger agreement terminated.

[Jeff Taitano]

https://backend.otcmarkets.com/otcapi/company/financial-report/270351/content

On March 26, 2018 an asset purchase agreement was entered with Immunotech Laboratories, Inc whereby the Exclusive License Agreement for the Patented Immunotherapy Treatment for the care of HIV/Aids and Hepatitis C patients, the Forty Nine Percent ownership in Immunotech Laboratories BG, all equipment and licensing of intellectual property associated with the Patented treatment in exchange for a secured note receivable, common stock of Enzolytics, Inc. issued to Immunotech Laboratories, Inc. and assumption of certain debt from Immunotech by Enzolytics, Inc.